A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity

Chung, Soo Jie; Kang, Sung Yoon; Kang, Rae Young; Kim, Young Chan; Lee, Kyung Hun; Kim, Tae Yong; Han, Sae Won; Kang, Hye Ryun

doi:10.1007/s00280-018-3662-0

Cited by 23 publications

(32 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This procedure allows the safe reintroduction of the drugs independently of the mechanisms . New nondilution, or 1‐solution, desensitization protocols are safe and effective for platinum agents' re‐administration . Besides, 12‐ and 16‐step rapid desensitization protocols are effective and safe for biologicals and antineoplastic agents .…”

Section: Novel Tools For Managing Dhrmentioning

confidence: 99%

“…23,173 Nowadays, desensitization is the only treatment for DHRs and is critical especially when patients need first-line therapy. 23,[174][175][176][177] This procedure allows the safe reintroduction of the drugs independently of the mechanisms. 178 New nondilution, or 1-solution, desensitization protocols are safe and effective for platinum agents' re-administration.…”

Section: Novel Tool S For Manag Ing Dhrmentioning

confidence: 99%

“…178 New nondilution, or 1-solution, desensitization protocols are safe and effective for platinum agents' re-administration. 175,179,180 Besides, 12-and 16-step rapid desensitization protocols are effective and safe for biologicals and antineoplastic agents. 15,176,181 Omalizumab has been used as adjuvant helping in the desensitization to oxaliplatin.…”

Section: Novel Tool S For Manag Ing Dhrmentioning

confidence: 99%

See 2 more Smart Citations

Recent developments and highlights in drug hypersensitivity

Mayorga

Fernandez

Montañez

et al. 2019

Allergy

View full text Add to dashboard Cite

Drug hypersensitivity reactions (DHRs) are nowadays the third cause of allergy after rhinitis and asthma with a significant increase in prevalence in both adults and paediatric population with new drugs included as culprit. For this, DHRs represent not only a health problem but also a significant financial burden for affected individuals and health systems. Mislabelling DHRs is showing to be a relevant problem for both, false label of drug allergic and false label of nonallergic. All this reinforces the need to improve accurate diagnostic approaches that allow an appropriate management.Moreover, there is a need for training both, nonallergist stakeholders and patients to improve the reaction identification and therefore decrease the mislabelling. The use of allergy cards has shown to be relevant to avoid the induction of DHRs due to the prescription of wrong medication.Recent developments over the last 2 years and highlights about risk factors, diagnostic approaches, mechanisms involved as well as prevention actions, and management have been reviewed. In these papers, it has been outlined the need for correct diagnosis and de-labelling of patients previously false-reported as allergic, which will improve the management and treatment of patients with DHRs. K E Y W O R D Sallergy diagnosis, allergy treatment, basic mechanisms, drug allergy, epidemiology | 2369

show abstract

Section: Novel Tools For Managing Dhrmentioning

confidence: 99%

Section: Novel Tool S For Manag Ing Dhrmentioning

confidence: 99%

Section: Novel Tool S For Manag Ing Dhrmentioning

confidence: 99%

See 1 more Smart Citation

Recent developments and highlights in drug hypersensitivity

Mayorga

Fernandez

Montañez

et al. 2019

Allergy

View full text Add to dashboard Cite

show abstract

“…RDD using 1-bag protocol has proven to be good in previous studies. In a previous study, 1-bag 12-step chemotherapy was successfully performed with platinum compounds, 19 In another retrospective cohort study, success rate and BTR frequency were not statistically different between 3-bag system and 1-bag system for paclitaxel administration. 10 In addition, when using the 1-bag system, it was possible to reduce the infusion time compared with the multi-bag protocol, thereby reducing the effort of medical staff.…”

Section: Discussionmentioning

confidence: 79%

“…The 1-bag, 12-step desensitization protocol was previously reported by Lee et al . 10 and Chung et al 19 and we performed desensitization with a modified protocol ( Fig. 1 ).…”

Section: Methodsmentioning

confidence: 99%

Does Carboplatin Rapid Desensitization Change Its Adverse Drug Reactions Other than Hypersensitivity and Efficacy in Patients With Ovarian Cancer?

Park

Lee

Kim

et al. 2020

Allergy Asthma Immunol Res

View full text Add to dashboard Cite

Purpose Rapid drug desensitization is known to be a good strategy in patients with drug hypersensitivity to chemotherapy. However, changes in maximal drug concentration and exposure time in blood through desensitization may alter other adverse reactions and efficacy of the drug. We investigated rapid desensitization for carboplatin in terms of severe adverse drug reactions (ADRs) and efficacy compared with the standard infusion. Methods A retrospective cohort study was conducted on patients with recurrent ovarian cancer who received carboplatin chemotherapy from 2017 to 2019. We compared serious adverse events (SAEs), ADRs according to organ classes, time to progression (TTP), and overall survival (OS). Results Of 108 desensitization procedures performed in 21 patients, 104 were successfully accomplished (96.3%). There were compared with 271 procedures in 41 patients who received the standard infusion method. There were 8 (7.7%) SAEs in the rapid desensitization group and 34 (12.5%) in the control group. One drug-related death occurred in the rapid desensitization group. In the rapid desensitized group, except for neutropenia, there was no statistically significant increase in SAEs and over grade 3 of ADRs according to organ classes compared with the control group. In the efficacy analysis, TTP and OS were similar in the 2 groups. Conclusions Rapid desensitization of carboplatin can lower the risk of immediate hypersensitivity reactions without changing the inherent effect and severe ADRs.

show abstract

Drug Desensitizations for Chemotherapy: Safety and Efficacy in Preventing Anaphylaxis

Caiado

Castells

2021

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity

Abstract: The new non-dilution desensitization protocol was safe and effective for re-administration of culprit platinum agents in patients with a history of HSRs. Therefore, this new protocol can be used as an alternative to existing protocols using multiple serial dilutions.

Cited by 23 publications

References 36 publications

Recent developments and highlights in drug hypersensitivity

Recent developments and highlights in drug hypersensitivity

Does Carboplatin Rapid Desensitization Change Its Adverse Drug Reactions Other than Hypersensitivity and Efficacy in Patients With Ovarian Cancer?

Drug Desensitizations for Chemotherapy: Safety and Efficacy in Preventing Anaphylaxis

Contact Info

Product

Resources

About